Supplementary file 1_Drug combination discovery assisted by AI and untargeted metabolomics: pamiparib and anlotinib synergistic potentiation for ovarian cancer treatment.docx

Supplementary file 1_Drug combination discovery assisted by AI and untargeted metabolomics: pamiparib and anlotinib synergistic potentiation for ovarian cancer treatment.docx

Background<p>The aim of this study was to investigate the mechanism of the Poly ADP-ribose polymerase (PARP) inhibitor pamiparib (PAM) and the tyrosine kinase inhibitor anlotinib (ANL), utilizing a Biological Factor Regulatory Neural Network (BFReg-NN) and metabolomics approach.</p>Metho...

Descrición completa

Gardado en:
Detalles Bibliográficos
Autor Principal: Dong Wang (73290) (author)
Outros autores: Baiwang Chu (22687046) (author), Tingjie Wen (22687049) (author), Xueyu Wang (1818046) (author), Ying Li (38224) (author), Hanning Chen (1723033) (author), Zhao Zhang (52732) (author), Hua Sun (406210) (author)
Publicado: 2025
Subjects:
Pharmacology
pamiparib
anlotinib
ovarian cancer
cancer stem cell (CSC)
untargeted metabolomics
artificial intelligence (AI)
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares